Overview

Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the efficacy on insulin sensitivity of GFT505 at 80mg/d in male patients with insulin resistance and abdominal obesity. Evaluation will be made using a glucose clamp technique.
Phase:
Phase 2
Details
Lead Sponsor:
Genfit
Treatments:
Insulin
Insulin, Globin Zinc